<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910424-0189</DOCNO><DOCID>910424-0189.</DOCID><HL>   Technology andamp; Science:   NIH Unit to Test Vaccine   For Aids of Genentech</HL><DATE>03/21/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B4</SO><CO>   GNE</CO><IN>MEDICAL AND BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><GV>HEALTH AND HUMAN SERVICES (HHS)</GV><LP>   SOUTH SAN FRANCISCO, Calif. -- Genentech Inc. said theNational Institute of Allergy and Infectious Diseases willbegin human clinical trials of its new AIDS vaccine this weekon a group of healthy volunteers.   The vaccine uses a gene-spliced version of a protein onthe virus's outer coat. It will be given by random assignmentto the first group of 10 volunteers who will receive 100micrograms of the vaccine. Four volunteers will be given aplacebo vaccine as part of the Phase I randomized study oftwo different dosages of the vaccine.</LP><TEXT>   Each volunteer will be given three injections, and thenwill be monitored for 52 weeks. If the vaccine proves safe,another 10 volunteers will be randomly assigned to receive300 micrograms of the vaccine, and four volunteers willreceive a placebo on the same timetable as the first round oftests.   Investigators will evaluate the clinical and immunologicsafety of the vaccine to &quot;determine its immune response andcompare them with the different doses.&quot; The tests will beconducted at Johns Hopkins University in Baltimore, and St.Louis University School of Medicine in St. Louis. NIAID,sponsor of the vaccine trial, is a unit of the NationalInstitutes of Health in Bethesda, Md.</TEXT></DOC>